The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2025, and HBC has today published the Annual Report and Sustainability Report for 2025. In October 2025, the Company announced a successful placing of new ordinary shares with gross proceeds of NOK 158 million. As of the date of this Annual report, the Company has yet to receive all share deposits and has therefore not completed the transaction. The primary cause of the delay is stated to be of a technical and le ...

Company Overview - Hofseth BioCare ASA (HBC) is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources [1] - The company upcycles by converting side streams of the salmon industry into health-improving ingredients for humans and pets [1] Product Offerings - HBC's key products include ProGo®, a mix of bioactive peptides and collagen, OmeGo®, a whole salmon oil, and CalGo® / NT-II® salmon bone powder [2] - ProGo® enhances iron metabolism, leading to increased energy and vitality [3] - OmeGo® provides immune health benefits and aids recovery from viral infections [3] - CalGo® supports bone and joint health, promoting healthy aging and active lifestyles [3] Scientific Research and Development - HBC emphasizes scientific evidence, resulting in academic partnerships and unique health benefit discoveries [3] - The company has secured patents for its findings and has identified potential therapeutics, leading to the establishment of HBC Immunology (HBCI) [3] - HBCI has raised external finance for its lead program targeting prostate cancer and ovarian cancer, along with a molecule aimed at asthma treatment [3] Corporate Structure and Location - HBC is headquartered in Ålesund, Norway, with branches in Oslo, London, Zürich, and Palo Alto [4] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [4]